Chimeric virus-like particles presenting tumour-associated MUC1 epitope result in high titers of specific IgG antibodies in the presence of squalene oil-in-water adjuvant: towards safe cancer immunotherapy
Abstract Background Immunotherapy is emerging as a powerful treatment approach for several types of cancers. Modulating the immune system to specifically target cancer cells while sparing healthy cells, is a very promising approach for safer therapies and increased survival of cancer patients. Tumou...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-03-01
|
| Series: | Journal of Nanobiotechnology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12951-022-01357-1 |
| _version_ | 1828115712439222272 |
|---|---|
| author | Mirosława Panasiuk Karolina Zimmer Anna Czarnota Magdalena Narajczyk Grażyna Peszyńska-Sularz Milena Chraniuk Lilit Hovhannisyan Sabina Żołędowska Dawid Nidzworski Anna J. Żaczek Beata Gromadzka |
| author_facet | Mirosława Panasiuk Karolina Zimmer Anna Czarnota Magdalena Narajczyk Grażyna Peszyńska-Sularz Milena Chraniuk Lilit Hovhannisyan Sabina Żołędowska Dawid Nidzworski Anna J. Żaczek Beata Gromadzka |
| author_sort | Mirosława Panasiuk |
| collection | DOAJ |
| description | Abstract Background Immunotherapy is emerging as a powerful treatment approach for several types of cancers. Modulating the immune system to specifically target cancer cells while sparing healthy cells, is a very promising approach for safer therapies and increased survival of cancer patients. Tumour-associated antigens are favorable targets for cancer immunotherapy, as they are exclusively expressed by the cancer cells, minimizing the risk of an autoimmune reaction. The ability to initiate the activation of the immune system can be achieved by virus-like particles (VLPs) which are safe and potent delivery tools. VLP‐based vaccines have evolved dramatically over the last few decades and showed great potential in preventing infectious diseases. Immunogenic potency of engineered VLPs as a platform for the development of effective therapeutic cancer vaccines has been studied extensively. This study involves recombinant VLPs presenting multiple copies of tumour-specific mucin 1 (MUC1) epitope as a potentially powerful tool for future immunotherapy. Results In this report VLPs based on the structural protein of Norovirus (NoV VP1) were genetically modified to present multiple copies of tumour-specific MUC1 epitope on their surface. Chimeric MUC1 particles were produced in the eukaryotic Leishmania tarentolae expression system and used in combination with squalene oil-in-water emulsion MF59 adjuvant to immunize BALB/c mice. Sera from vaccinated mice demonstrated high titers of IgG and IgM antibodies which were specifically recognizing MUC1 antigen. Conclusions The obtained results show that immunization with recombinant chimeric NoV VP1- MUC1 VLPs result in high titers of MUC1 specific IgG antibodies and show great therapeutic potential as a platform to present tumour-associated antigens. Graphical Abstract |
| first_indexed | 2024-04-11T12:45:41Z |
| format | Article |
| id | doaj.art-e0040c6254a245bb9d66a79b77e57b05 |
| institution | Directory Open Access Journal |
| issn | 1477-3155 |
| language | English |
| last_indexed | 2024-04-11T12:45:41Z |
| publishDate | 2022-03-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Nanobiotechnology |
| spelling | doaj.art-e0040c6254a245bb9d66a79b77e57b052022-12-22T04:23:23ZengBMCJournal of Nanobiotechnology1477-31552022-03-0120111310.1186/s12951-022-01357-1Chimeric virus-like particles presenting tumour-associated MUC1 epitope result in high titers of specific IgG antibodies in the presence of squalene oil-in-water adjuvant: towards safe cancer immunotherapyMirosława Panasiuk0Karolina Zimmer1Anna Czarnota2Magdalena Narajczyk3Grażyna Peszyńska-Sularz4Milena Chraniuk5Lilit Hovhannisyan6Sabina Żołędowska7Dawid Nidzworski8Anna J. Żaczek9Beata Gromadzka10Intercollegiate Faculty of Biotechnology, University of Gdańsk and Medical University of GdańskIntercollegiate Faculty of Biotechnology, University of Gdańsk and Medical University of GdańskIntercollegiate Faculty of Biotechnology, University of Gdańsk and Medical University of GdańskLaboratory of Electron Microscopy, Faculty of Biology, University of GdańskTri-City Central Animal Laboratory Research and Service Center, Medical University of GdańskDepartment of in vitro Studies, Institute of Biotechnology and Molecular MedicineDepartment of in vitro Studies, Institute of Biotechnology and Molecular MedicineInstitute of Biotechnology and Molecular MedicineInstitute of Biotechnology and Molecular MedicineLaboratory of Translational Oncology, Medical University of GdańskIntercollegiate Faculty of Biotechnology, University of Gdańsk and Medical University of GdańskAbstract Background Immunotherapy is emerging as a powerful treatment approach for several types of cancers. Modulating the immune system to specifically target cancer cells while sparing healthy cells, is a very promising approach for safer therapies and increased survival of cancer patients. Tumour-associated antigens are favorable targets for cancer immunotherapy, as they are exclusively expressed by the cancer cells, minimizing the risk of an autoimmune reaction. The ability to initiate the activation of the immune system can be achieved by virus-like particles (VLPs) which are safe and potent delivery tools. VLP‐based vaccines have evolved dramatically over the last few decades and showed great potential in preventing infectious diseases. Immunogenic potency of engineered VLPs as a platform for the development of effective therapeutic cancer vaccines has been studied extensively. This study involves recombinant VLPs presenting multiple copies of tumour-specific mucin 1 (MUC1) epitope as a potentially powerful tool for future immunotherapy. Results In this report VLPs based on the structural protein of Norovirus (NoV VP1) were genetically modified to present multiple copies of tumour-specific MUC1 epitope on their surface. Chimeric MUC1 particles were produced in the eukaryotic Leishmania tarentolae expression system and used in combination with squalene oil-in-water emulsion MF59 adjuvant to immunize BALB/c mice. Sera from vaccinated mice demonstrated high titers of IgG and IgM antibodies which were specifically recognizing MUC1 antigen. Conclusions The obtained results show that immunization with recombinant chimeric NoV VP1- MUC1 VLPs result in high titers of MUC1 specific IgG antibodies and show great therapeutic potential as a platform to present tumour-associated antigens. Graphical Abstracthttps://doi.org/10.1186/s12951-022-01357-1Cancer immunotherapyCancer vaccinesVLPsBioengineered nanostructuresMUC1 |
| spellingShingle | Mirosława Panasiuk Karolina Zimmer Anna Czarnota Magdalena Narajczyk Grażyna Peszyńska-Sularz Milena Chraniuk Lilit Hovhannisyan Sabina Żołędowska Dawid Nidzworski Anna J. Żaczek Beata Gromadzka Chimeric virus-like particles presenting tumour-associated MUC1 epitope result in high titers of specific IgG antibodies in the presence of squalene oil-in-water adjuvant: towards safe cancer immunotherapy Journal of Nanobiotechnology Cancer immunotherapy Cancer vaccines VLPs Bioengineered nanostructures MUC1 |
| title | Chimeric virus-like particles presenting tumour-associated MUC1 epitope result in high titers of specific IgG antibodies in the presence of squalene oil-in-water adjuvant: towards safe cancer immunotherapy |
| title_full | Chimeric virus-like particles presenting tumour-associated MUC1 epitope result in high titers of specific IgG antibodies in the presence of squalene oil-in-water adjuvant: towards safe cancer immunotherapy |
| title_fullStr | Chimeric virus-like particles presenting tumour-associated MUC1 epitope result in high titers of specific IgG antibodies in the presence of squalene oil-in-water adjuvant: towards safe cancer immunotherapy |
| title_full_unstemmed | Chimeric virus-like particles presenting tumour-associated MUC1 epitope result in high titers of specific IgG antibodies in the presence of squalene oil-in-water adjuvant: towards safe cancer immunotherapy |
| title_short | Chimeric virus-like particles presenting tumour-associated MUC1 epitope result in high titers of specific IgG antibodies in the presence of squalene oil-in-water adjuvant: towards safe cancer immunotherapy |
| title_sort | chimeric virus like particles presenting tumour associated muc1 epitope result in high titers of specific igg antibodies in the presence of squalene oil in water adjuvant towards safe cancer immunotherapy |
| topic | Cancer immunotherapy Cancer vaccines VLPs Bioengineered nanostructures MUC1 |
| url | https://doi.org/10.1186/s12951-022-01357-1 |
| work_keys_str_mv | AT mirosławapanasiuk chimericviruslikeparticlespresentingtumourassociatedmuc1epitoperesultinhightitersofspecificiggantibodiesinthepresenceofsqualeneoilinwateradjuvanttowardssafecancerimmunotherapy AT karolinazimmer chimericviruslikeparticlespresentingtumourassociatedmuc1epitoperesultinhightitersofspecificiggantibodiesinthepresenceofsqualeneoilinwateradjuvanttowardssafecancerimmunotherapy AT annaczarnota chimericviruslikeparticlespresentingtumourassociatedmuc1epitoperesultinhightitersofspecificiggantibodiesinthepresenceofsqualeneoilinwateradjuvanttowardssafecancerimmunotherapy AT magdalenanarajczyk chimericviruslikeparticlespresentingtumourassociatedmuc1epitoperesultinhightitersofspecificiggantibodiesinthepresenceofsqualeneoilinwateradjuvanttowardssafecancerimmunotherapy AT grazynapeszynskasularz chimericviruslikeparticlespresentingtumourassociatedmuc1epitoperesultinhightitersofspecificiggantibodiesinthepresenceofsqualeneoilinwateradjuvanttowardssafecancerimmunotherapy AT milenachraniuk chimericviruslikeparticlespresentingtumourassociatedmuc1epitoperesultinhightitersofspecificiggantibodiesinthepresenceofsqualeneoilinwateradjuvanttowardssafecancerimmunotherapy AT lilithovhannisyan chimericviruslikeparticlespresentingtumourassociatedmuc1epitoperesultinhightitersofspecificiggantibodiesinthepresenceofsqualeneoilinwateradjuvanttowardssafecancerimmunotherapy AT sabinazołedowska chimericviruslikeparticlespresentingtumourassociatedmuc1epitoperesultinhightitersofspecificiggantibodiesinthepresenceofsqualeneoilinwateradjuvanttowardssafecancerimmunotherapy AT dawidnidzworski chimericviruslikeparticlespresentingtumourassociatedmuc1epitoperesultinhightitersofspecificiggantibodiesinthepresenceofsqualeneoilinwateradjuvanttowardssafecancerimmunotherapy AT annajzaczek chimericviruslikeparticlespresentingtumourassociatedmuc1epitoperesultinhightitersofspecificiggantibodiesinthepresenceofsqualeneoilinwateradjuvanttowardssafecancerimmunotherapy AT beatagromadzka chimericviruslikeparticlespresentingtumourassociatedmuc1epitoperesultinhightitersofspecificiggantibodiesinthepresenceofsqualeneoilinwateradjuvanttowardssafecancerimmunotherapy |